Am
Non verificato

Amylyx Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network
05/12/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
1.00
06/11/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
1.00
03/11/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Web e Social Network
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
1.00
30/10/2025
Salute
Scienza
Sanità
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
1.00
10/09/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
1.00
09/09/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Finanza
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
1.00
27/08/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Industria
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
1.00
26/08/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Web e Social Network
Eventi
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
1.00
07/08/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Web e Social Network
Telefonia e Varie
Mercato azionario
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
1.00
31/07/2025
Salute
Sanità
Scienza
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0